Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN 55905, USA.
Gut. 2010 Sep;59(9):1288-96. doi: 10.1136/gut.2009.199653.
Chronic constipation affects almost one in six adults and is even more frequent in the elderly. In the vast majority of patients, there is no obstructive mucosal or structural cause for constipation and, after excluding relatively rare systemic diseases (commonest of which is hypothyroidism), the differential diagnosis is quickly narrowed down to three processes: evacuation disorder of the spastic (pelvic floor dyssynergia, anismus) or flaccid (descending perineum syndrome) varieties, and normal or slow transit constipation. Treatment of chronic constipation based on identifying the underlying pathophysiology is generally successful with targeted therapy. The aims of this review are to discuss targeted therapy for chronic constipation: behavioural treatment for outlet dysfunction and pharmacological treatment for constipation not associated with outlet dysfunction. In particular, we shall review the evidence that behavioural treatment works for evacuation disorders, describe the new treatment options for constipation not associated with evacuation disorder, and demonstrate how 'targeting therapy' to the underlying diagnosis results in a balanced approach to patients with these common disorders.
慢性便秘影响近六分之一的成年人,在老年人中更为常见。在绝大多数患者中,便秘没有阻塞性黏膜或结构原因,在排除相对罕见的系统性疾病(最常见的是甲状腺功能减退症)后,鉴别诊断很快缩小到三个过程:痉挛性(盆底协同失调、肛门失弛缓症)或弛缓性(会阴下降综合征)排空障碍,以及正常或缓慢传输性便秘。基于确定潜在病理生理学的慢性便秘治疗通常通过靶向治疗获得成功。本综述的目的是讨论慢性便秘的靶向治疗:出口功能障碍的行为治疗和与出口功能障碍无关的便秘的药物治疗。特别是,我们将回顾行为治疗对排空障碍有效的证据,描述与排空障碍无关的便秘的新治疗选择,并展示如何针对潜在诊断进行“靶向治疗”,从而为这些常见疾病患者提供平衡的治疗方法。